Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
23.23
-0.36 (-1.53%)
At close: Jan 22, 2025, 4:00 PM
23.41
+0.18 (0.77%)
After-hours: Jan 22, 2025, 5:32 PM EST
Immunovant Employees
Immunovant had 207 employees as of March 31, 2024. The number of employees increased by 43 or 26.22% compared to the previous year.
Employees
207
Change (1Y)
43
Growth (1Y)
26.22%
Revenue / Employee
n/a
Profits / Employee
-$1,560,415
Market Cap
3.41B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IMVT News
- 26 days ago - Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study - Seeking Alpha
- 6 weeks ago - FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial - GlobeNewsWire
- 2 months ago - Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 3 months ago - Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - GlobeNewsWire
- 4 months ago - Top 2 Health Care Stocks That May Collapse This Quarter - Benzinga
- 4 months ago - Immunovant Provides Update on Graves' Disease Development Program - GlobeNewsWire
- 4 months ago - Immunovant to Host Graves' Disease Program Update on September 9, 2024 - GlobeNewsWire
- 6 months ago - Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging - Seeking Alpha